<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587728</url>
  </required_header>
  <id_info>
    <org_study_id>20140503</org_study_id>
    <nct_id>NCT02587728</nct_id>
  </id_info>
  <brief_title>Carpal Tunnel/Amyloidosis Blood Sample Study</brief_title>
  <official_title>Collection of Peripheral Blood Samples From Patients With Carpal Tunnel Syndrome for Laboratory Screening of Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carpal tunnel is an early manifestation of amyloidosis in a significant minority of patients.&#xD;
      This specimen collection protocol will allow the investigators to screen patients with carpal&#xD;
      tunnel syndrome for amyloidosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to assess a high risk population of patients, those with carpal&#xD;
      tunnel syndrome, and systematically assess them for Amyloid Light-chain (AL) amyloidosis and&#xD;
      Transthyretin-Related Amyloidosis (ATTR) with simple laboratory blood tests. The combination&#xD;
      of serum immunofixation electrophoresis together with serum free light chain (FLC) assay&#xD;
      approaches 100% sensitivity for identifying the monoclonal protein underlying the illness in&#xD;
      patients with AL amyloidosis. In addition to this, testing for transthyretin gene mutations&#xD;
      will allow the investigators to identify patients with ATTR. The investigators believe this&#xD;
      simple screening panel (serum immunofixation and serum FLC assay and transthyretin mutation&#xD;
      analysis) may allow the investigators to identify patients early in the course of their&#xD;
      disease, at which point the investigators can intervene with effective treatment and spare&#xD;
      patients a significant amount of morbidity and mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2016</start_date>
  <completion_date type="Actual">February 7, 2017</completion_date>
  <primary_completion_date type="Actual">February 7, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Identified with Amyloidosis</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Number of carpal tunnel syndrome patients identified with amyloidosis, which will be stratified into mild, moderate or severe</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Carpal Tunnel Syndrome</condition>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Carpal Tunnel Blood Draw</arm_group_label>
    <description>Participants with confirmed diagnosis of Carpal Tunnel Syndrome who will undergo blood draw for laboratory analysis for amyloidosis.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Genome DNA extracted peripheral blood mononuclear cells (PBMCs)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients within 24 months of confirmed diagnosis of Carpal Tunnel Syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patients with diagnosed carpal tunnel syndrome based on Electromyography (EMG)&#xD;
             results.&#xD;
&#xD;
          -  2. Patients with electrographic confirmation of median neuropathy at the wrist&#xD;
&#xD;
          -  3. Age â‰¥18 years&#xD;
&#xD;
          -  4. Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients receiving hemodialysis&#xD;
&#xD;
          -  2. Known amyloidosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Hoffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>James Hoffman, MD</investigator_full_name>
    <investigator_title>Associate Professor of Clinical</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

